ABBOTT HEALTHCARE PVT. LTD

Similar documents
No /46/2016-PI.I GOVERNMENT OF INDIA MINISTRY OF CHEMICALS & FERTILIZERS DEPARTMENT OF PHARMACEUTICALS

What s New NPPA has fixed/revised ceiling prices/retail Prices of 65 formulations under Drugs

Minutes of the 192nd (overall) and 60th meeting of the Authority under DPCO, 2013 held on at 11:30 AM

PROJECT: EGGS OF ANT

Bundelkhand University, Jhansi

भ रत य व ज ञ न श क ष ए अन स ध न स स थ न भ ऩ ऱ

What s New

CHINMAYA VIDYALAYA HOLIDAY HOMEWORK ( ) CLASS II

भ रत य व न श एव अन स ध न स स थ न भ प ल

Rate In Rs.Ps (ED Included. Tax Extra) Sl No Name Of The Product Pack. Scheduled And Non-Scheduled Formulations Capsules

SADHU VASWANI INTERNATIONAL SCHOOL FOR GIRLS SHANTINIKETAN, NEW DELHI

Apeejay School, Sheikh Sarai-I Holidays Homework. Class II

Annual Report

Retail Price (excluding local taxes, if any,) fixed under Para 5, 11 and 15 of DPCO, Manufacturer and Marketing Company respectively

3 party manufacturing PRODUCT LIST. Category : ANTI BIOTIC

West Enclave, Pitampura, Delhi Ph: , Fax: Web: brilliantsconvent.

FDA MedWatch. KCER Release Date: November

The rights of patients as consumers: An ancient view

MEDICINES CONTROL COUNCIL

Retail Price (excluding local taxes, if any,) fixed under Para 5, 11 and 15 of DPCO, Manufacturer and Marketing Company respectively

Public Assessment Report Scientific discussion. Amlodipin Accord (amlodipine besilate)

MANUFACTURING PROBLEMS AS OF 22nd June 2018

CHINMAYA VIDYALAYA HOLIDAY HOMEWORK ( ) CLASS -V VACATION TIME, A TIME TO UNWIND, SWITCH ON THE SEARCH ENGINES OF YOUR MIND,

Approved Drug Product List - Orange Book Reference Listed Drugs by ANDA Reference Standard List. April 2017 Page 1 of 6

MEDICINES CONTROL COUNCIL

Manufacturer and Marketing Company respectively. M/s Cris Pharma (India) Limited / M/s Seagull Pharmaceuticals Pvt. Ltd.

Fedley healthcare Pvt. Ltd.

DELHI PUBLIC SCHOOL, SRINAGAR MATHEMATICS CLASS VII

PRODUCT-LIST KENVISH HEALTHCARE

Kāsiga School. Sample Question Paper. English Hindi Math Science ENGLISH. Q1. Write a paragraph on the following topic: A Family Picnic.

Lot # Exp. Date Product Description / Strength Bottle Size NDC. 23X017 11/2018 Amlodipine and Valsartan Tablets 5 mg/160 mg 90 Count

MEDICINES CONTROL COUNCIL

MEDICINES CONTROL COUNCIL

Class I Recall CLASS I RECALL

ABOUT US. Veterinary Pharmaceutical Franchisee Outlets ( Siflon Vet Pharma), PTFE components ( Siflon Polymers),

BIODATA. (V) P.G.D.E.A.M. (Manag) NIAEM (NAARM) Hyderabad- First Division.

Amoxicillin 500 teva. Call or

Deptt of Pharma Science SGRR ITS Patel Nagar, Dehradun (UK)

Working group session

Retail Price (excluding local taxes, if any,) fixed under Para 5, 11 and 15 of DPCO, Sr.No. S.O.No Date Formulation based on bulk drugs

Efficacy of Moxidectin 6-Month Injectable and Milbemycin Oxime/Lufenuron Tablets Against Naturally Acquired Toxocara canis Infections in Dogs*

New Products.


QUALITY HEALTH CARE YOUR PREFERRED PARTNER IN. For better health

UNDERSTANDING SOUTH AFRICA'S CONSUMPTION OF ANTIMICROBIALS

QUALITY AND AFFORDABILITY OF AMOXICILLIN GENERIC PRODUCTS: A PATIENT CONCERN

Should you have any questions, please contact Edith Chang, Ph.D., Senior Scientific Liaison ( or

AMOXICILLIN AND CLAVULANIC ACID TABLETS Draft proposal for The International Pharmacopoeia (February 2018)

Public Assessment Report Scientific discussion


See Important Reminder at the end of this policy for important regulatory and legal information.

Quality of 2 nd line medicines for tuberculosis. Ms Lisa Hedman World Health Organization Department of Essential Medicines and Health Products

Tamboli Ashpak Mubarak et al. IRJP 2 (8)

म ट द न व ल पश ओ क ए ट -म टम और प स ट-म टम ननर क षण क र नत स ह त

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

See Important Reminder at the end of this policy for important regulatory and legal information.

Dr. Subhasish Sahu. Scientist

8 Formulaton, evaluation and optimization of immediate release layer of amlodipine besylate

Compliance. Should you have any questions, please contact Praveen Pabba, Ph.D., ( or

3rd Partners Meeting on Better Medicines for Children. Update Ecumenical Pharmaceutical Network / EPN

Amoxicillin Mg Dosage

Spectrophotometric Method for Simultaneous Estimation of Amlodipine Besylate in Pharmaceutical Formulation

Maan Medex Private Limited

Immunization Administration Procedure Code Changes Effective April 1, 2011

URJA Newsletter. Focus on Implementing Policies Rather Than Creating New Ones. Inside this issue: Street Dogs/ 2-3 Smart RWA

NEW. paralysis ticks fleas heartworm intestinal worms

Omeprazole Capsule TAJ GROUP PHARMACEUTICAL B U S I N E S S. Generics

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Antibiotics.

The 4 th Generation calcium channel blocker C I L N I D I P I N E

SUMMARY of PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Pentoject, Pentobarbitone Sodium 200 mg/ml Solution for Injection

IN-VIVO EVALUATION OF ANTI-COCCIDIAL EFFICACY OF SALINOMYCIN AND AMPROLIUM IN COMMERCIAL CHICKEN

Dosing Your Cat with Azithromycin Pediatric Suspension. By Lorraine Shelton

MATERIAL SAFETY DATA SHEET

PO. Vasan, Gandhinagar District, Gujarat, India, 3 Dean at Faculty of Pharmacy, Dharmsinh Desai University, Nadiad, Gujarat, India.

Pharma Research Library. 2013, Vol. 1(1):19-29

MEDICINES CONTROL COUNCIL

HSE - Health Protection Surveillance Centre Surveillance of Antimicrobial Consumption in Ireland

Manufacturer and Marketing Company respectively M/s Unison Pharmaceuticals Pvt. Ltd. M/s Unison Pharmaceuticals Pvt. Ltd.

Active Constituent: Each tablet contains 500 mg cephalexin (as monohydrate) Contents: 12 [100, 300] Tablets

ANALYSIS OF REPRODUCTIVE DISORDERS IN DAIRY ANIMALS IN ALWAR DISTRICT OF RAJASTHAN

LUPIN LIMITED SAFETY DATA SHEET. Section 1: Identification MADE IN INDIA

Active Constituent: Each tablet contains 1000 mg cephalexin (as monohydrate) Contents: 8 [100, 300] Tablets

Canine Behavior History Form Please complete and return form to GreenTree Animal Hospital 48 hours prior to your appointment.

THE MONTHLY ASSENT (August-October issue) PROUD TO BE AN ASCENDITE!

MEDICINES CONTROL COUNCIL

International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep

Centre for Science and Environment recommendations: Modifications in Drugs and Cosmetics Act (1940) and Rules (1945)

PARASITE TREATMENTS PROVEN PROTECTION FOR DOGS AND CATS

Summary of product characteristics As per Annex C. SUMMARY OF PRODUCT CHARACTERISTICS Doc. No. SPC/71108 Ver.1

Medicine Price Monitor

Public Assessment Report. Scientific discussion. Xiflodrop 5 mg/ml eye drops, solution. Moxifloxacin hydrochloride DK/H/2221/001/DC

Hydroxyzine Hcl 25 Mg Tablet High

Epidemiology and Economics of Antibiotic Resistance

Keflex Price Rite Aid

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: Oregon Health Plan

- { PAGE } - GOVERNMENT OF RAJASTHAN DIRECTORATE MEDICAL, HEALTH F.W. SERVICES RAJASTHAN, JAIPUR

COST VARIATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS AVAILABLE IN INDIAN MARKET: AN ECONOMIC PERSPECTIVE

Drug Utilization Evalauation of Antibiotics in Dh Uttarakashi

Transcription:

Computation of Retail Price based on Dec., 2015 Data under Para 4 of DPCO 2013 Diclofenac Gel 1% of M/s Blue Cross Labs Pvt. Ltd./M/s The Madras Pharmaceuticals Number of Companies cosisting of Market Share of 1% & Above 11 Sum of MAT value considered for price calculation (in Lakhs) 20954.43 Sum of PTR per unit considered for price calculation 56.76 Number of Packs considered 27 Average PTR 2.10 Add : 16% Retailer Margin 0.34 Retail Price (without local taxes) 2.44 % Reduction with compared to Highest Price 21.64% Strength Pack Size TOTAL MAT 2,174,844,340 100% Unit PTR (Rs.) MAT (Rs.) SKU wise MAT % Levelwise MAT (ignoring O% MAT) Minimumum Price (Rs.) 1.41 Maximum Price (Rs.) 2.68 Average of all considered (Rs.) 2.10 Retail Price (Rs.) 2.44 1 DICLOFENAC M2A2 ESGIPYRIN INSTA 1 % GEL 30 GM ESGIPYRIN ABBOTT HEALTHCARE PVT. LTD 1 % 30 GM 63.52 14,478,939 0.67% 1.06% Y 2.12 2.12 2 DICLOFENAC M2A2 TOPACFAST 1 % GEL 20 GM TOPACFAST ABBOTT HEALTHCARE PVT. LTD 1 % 20 GM 29.33 8,512,861 0.39% 1.06% Y 1.47 1.47 3 DICLOFENAC M2A2 DOLENTIA GEL 1 % GEL 30 GM DOLENTIA GEL AKUMENTIS HEALTHCARE LTD 1 % 30 GM 49.52 7,853,723 0.36% 0.36% N 1.65 4 DICLOFENAC M2A2 ANAFLAM 30 GM GEL ANAFLAM GEL ALBERT DAVID LTD. 1 % 20 GM 51.57 16,261,186 0.75% 0.75% N 2.58 5 DICLOFENAC M2A2 ENZOFLAM MICRO 1 % GEL 30 GM ENZOFLAM ALKEM LABORATORIES LTD. 1 % 30 GM 73.12 892,649 0.04% 0.04% N 2.44 6 DICLOFENAC M2A2 DICLODYNE 1 % GEL 30 GM DICLODYNE BLISS CHEMICAL& PHARMACEUTICALS LTD 1 % 30 GM 48.51 618,551 0.03% 0.03% N 1.62 7 DICLOFENAC M2A2 DICLOTAL 1 % GEL 30 GM DICLOTAL BLUE CROSS LABORATORIES LTD 1 % 30 GM 51.81 179,555 0.01% 0.01% N 1.73 8 DICLOFENAC M2A2 DD (DALES) 1 % GEL 30 GM DD (DALES) DALES PHARMACEUTICALS LTD 1 % 30 GM 45.71 895,367 0.04% 0.04% N 1.52 9 DICLOFENAC M2A2 NEXONAC 1 % GEL 30 GM NEXONAC EMENOX HEALTHCARE PVT LTD 1 % 30 GM 60.95 579,878 0.03% 0.03% N 2.03 10 DICLOFENAC M2A2 ALOCK 1 % GEL 30 GM ALOCK GODDRES PHARMACEUTICALS LTD 1 % 30 GM 60.95 2,773,225 0.13% 0.13% N 2.03 11 DICLOFENAC M2A2 PAINOXOL 1 % GEL 30 GM PAINOXOL GRAF LABORATORIES PVT LTD 1 % 30 GM 41.14 140,220 0.01% 0.01% N 1.37 12 DICLOFENAC M2A2 XEROFLAM ULTRA 1 % GEL 30 GM XEROFLAM ULTRA HELIOS PHARMACEUTICALS 1 % 30 GM 68.57 4,807,374 0.22% 0.22% N 2.29 13 DICLOFENAC M2A2 JUSGO 30 GM GEL JUSGO GEL INDI PHARMA PVT. LTD. 1 % 30 GM 61.54 25,000,000 1.15% 1.15% Y 2.05 2.05 14 DICLOFENAC M2A2 3D 1 % GEL 30 GM 3D INTAS PHARMACEUTICALS LTD 1 % 30 GM 7.25 1,127,332 0.05% 0.05% N 0.24 15 DICLOFENAC M2A2 DICLORAN 10 MG GEL 20 GM DICLORAN JB CHEMICALS 1 % 20 GM 79.18 382,870 0.02% 0.02% N 3.96 16 DICLOFENAC M2A2 POWERGESIC PLUS 1 % GEL 30 GM POWERGESIC PLUS JENBURKT PHARMACEUTICALS LTD 1 % 30 GM 69.33 51,318,026 2.36% 2.36% Y 2.31 2.31 17 DICLOFENAC M2A2 ADIFLAM 1 % GEL 30 GM ADIFLAM LEBEN LABORATORIES PVT.LTD 1 % 30 GM 26.08 2,883,301 0.13% 0.13% N 0.87 18 DICLOFENAC M2A2 VIVIAN 30 GM GEL VIVIAN GEL LINCOLN PHARMACEUTICALS LTD. 1 % 30 GM 48.62 14,064,984 0.65% 0.65% N 1.62 19 DICLOFENAC M2A2 DICLONAC 1 % GEL 30 GM DICLONAC LUPIN LTD 1 % 30 GM 72.32 1,802,438 0.08% 0.44% N 2.41 20 DICLOFENAC M2A2 DICLONAC TRANSGEL 1 % GEL 30 GM DICLONAC TRANSGEL LUPIN LTD 1 % 30 GM 72.32 7,872,596 0.36% 0.44% N 2.41 21 DICLOFENAC M2A2 VOZOX 1 % GEL 30 GM VOZOX MACMILLON PHARMACEUTICALS 1 % 30 GM 52.98 601,164 0.03% 0.03% N 1.77 22 DICLOFENAC M2A2 DUOFLAM 15 GM GEL DUOFLAM GEL MANEESH PHARMACEUTICALS LTD. 1 % 15 GM 35.56 3,420,907 0.16% 0.41% N 2.37 23 DICLOFENAC M2A2 DUOFLAM 30 GM GEL DUOFLAM GEL MANEESH PHARMACEUTICALS LTD. 1 % 30 GM 59.11 5,489,132 0.25% 0.41% N 1.97 24 DICLOFENAC M2A2 NOBEL10 GM GEL NOBEL GEL MANKIND 1 % 10 GM 17.05 33,600,000 1.54% 4.75% Y 1.71 1.71 25 DICLOFENAC M2A2 NOBEL 30 GM GEL NOBEL GEL MANKIND 1 % 30 GM 42.41 69,800,000 3.21% 4.75% Y 1.41 1.41 26 DICLOFENAC M2A2 DIVON 1 % GEL 10 GM DIVON MICRO LABS LTD 1 % 10 GM 24.27 10,603,165 0.49% 1.40% Y 2.43 2.43 27 DICLOFENAC M2A2 DIVON 1 % GEL 30 GM DIVON MICRO LABS LTD 1 % 30 GM 66.21 19,790,553 0.91% 1.40% Y 2.21 2.21 28 DICLOFENAC M2A2 VOVERAN EMULGEL 1 % GEL 21 GM VOVERAN NOVARTIS INDIA LTD 1 % 21 GM 53.26 62,360,616 2.87% 8.45% Y 2.54 2.54 29 DICLOFENAC M2A2 VOVERAN EMULGEL 1 % GEL 50 GM VOVERAN NOVARTIS INDIA LTD 1 % 50 GM 133.92 71,683,870 3.30% 8.45% Y 2.68 2.68 30 DICLOFENAC M2A2 VOVERAN TPM 1 % GEL 30 GM VOVERAN NOVARTIS INDIA LTD 1 % 30 GM 80.34 49,493,321 2.28% 8.45% Y 2.68 2.68 31 DICLOFENAC M2A2 MISONAC 1 % GEL 30 GM MISONAC ORDAIN HEALTHCARE PVT. LTD 1 % 30 GM 66.36 2,042,960 0.09% 0.09% N 2.21 32 DICLOFENAC M2A2 DFO GEL 30GM DFO OZONE PHARMACUUTICALS LTD. 1 % 30 GM 60.81 152,805,528 7.03% 7.59% Y 2.03 2.03 33 DICLOFENAC M2A2 DFO GEL 30GM DFO OZONE PHARMACUUTICALS LTD. 1 % 30 GM 56.07 12,083,379 0.56% 7.59% Y 1.87 1.87 34 DICLOFENAC M2A2 DOLFRE 1 % GEL 30 GM DOLFRE RAVENBHEL PHARMACEUTICALS PVT LTD. 1 % 30 GM 56.07 1,379,730 0.06% 0.06% N 1.87 35 DICLOFENAC M2A2 TRAUMANIL(RUI) 1 % GEL 30 GM TRAUMANIL(RUI) RUSI REMEDIES P. LTD. 1 % 30 GM 41.72 307,908 0.01% 0.01% N 1.39 36 DICLOFENAC M2A2 VOLINI 30 GM GEL VOLINI GEL SUN PHARMA 1 % 30 GM 69.27 524,918,617 24.14% 55.65% Y 2.31 2.31 37 DICLOFENAC M2A2 VOLINI 15 GM GEL VOLINI GEL SUN PHARMA 1 % 15 GM 38.49 281,026,988 12.92% 55.65% Y 2.57 2.57 38 DICLOFENAC M2A2 VOLINI 50 GM GEL VOLINI GEL SUN PHARMA 1 % 50 GM 103.91 193,753,868 8.91% 55.65% Y 2.08 2.08 39 DICLOFENAC M2A2 VOLINI 75 GM GEL VOLINI GEL SUN PHARMA 1 % 75 GM 142.40 143,292,242 6.59% 55.65% Y 1.90 1.90 40 DICLOFENAC M2A2 VOLINI 10 GM GEL VOLINI GEL SUN PHARMA 1 % 10 GM 20.78 26,715,703 1.23% 55.65% Y 2.08 2.08 41 DICLOFENAC M2A2 VOLINI 100 GM GEL VOLINI GEL SUN PHARMA 1 % 100 GM 165.54 21,526,491 0.99% 55.65% Y 1.66 1.66 42 DICLOFENAC M2A2 VOLINI 5 GM GEL VOLINI GEL SUN PHARMA 1 % 5 GM 7.93 19,015,640 0.87% 55.65% Y 1.59 1.59 43 DICLOFENAC M2A2 SYSTAFLAM 1 % GEL 25 GM SYSTAFLAM SYSTOPIC LABORATORIES LTD-MEM 1 % 25 GM 50.03 39,529,078 1.82% 2.68% Y 2.00 2.00 44 DICLOFENAC M2A2 SYSTAFLAM 1 % GEL 50 GM SYSTAFLAM SYSTOPIC LABORATORIES LTD-MEM 1 % 50 GM 76.22 18,736,248 0.86% 2.68% Y 1.52 1.52 45 DICLOFENAC M2A2 DICLODYNE 1 % GEL 30 GM DYNAPAR TROIKKA PHARMACEUTICALS LTD. 1 % 30 GM 68.57 38,320,000 1.76% 1.76% Y 2.29 2.29 46 DICLOFENAC M2A2 DICLOWIN PLUS 1 % GEL 30 GM DICLOWIN PLUS WINGS PHARMACEUTICALS PVT. LTD. 1 % 30 GM 28.00 1,620,818 0.07% 0.07% N 0.93 47 DICLOFENAC M2A2 DICLOMOL 1 % GEL 20 GM DICLOMOL WIN-MEDICARE PVT. LTD. 1 % 20 GM 62.10 332,122 0.02% 0.02% N 3.11 Qualify (Y/N) (Y=Yes N=No) Unit

Strength Pack Size Unit PTR (Rs.) MAT (Rs.) SKU wise MAT % Levelwise MAT (ignoring O% MAT) 48 DICLOFENAC M2A2 MOBIGEL 1 % GEL 25 GM MOBIGEL YASH PHARMA LABORATORIES 1 % 25 GM 50.29 1,070,977 0.05% 0.05% N 2.01 49 DICLOFENAC M2A2 ACTIVA 1 % GEL 30 GM ACTIVA ZYDUS CADILA 1 % 30 GM 71.20 188,395 0.01% 9.52% Y 2.37 2.37 50 DICLOFENAC M2A2 OXALGIN 1 % GEL 30 GM OXALGIN ZYDUS CADILA 1 % 30 GM 69.27 6,629,575 0.30% 9.52% Y 2.31 2.31 51 DICLOFENAC M2A2 OXALGIN NANO 1 % GEL 50 GM OXALGIN NANO ZYDUS CADILA 1 % 50 GM 113.15 8,637,010 0.40% 9.52% Y 2.26 2.26 52 DICLOFENAC M2A2 OXALGIN NANO 10 MG GEL 30 GM OXALGIN NANO ZYDUS CADILA 1 % 30 GM 69.27 191,623,260 8.81% 9.52% Y 2.31 2.31 Rs. Per Tablet Worked out Retail Price 2.44 Claimed Retail Price 2.67 Already notified Retail Price + 10% 2.32 increase for 1 year Proposed Retail Price 2.32 Qualify (Y/N) (Y=Yes N=No) Unit

ड प स ओ 2013 क प र 4 क तहत, अगस त 2015 क आ कड क आध ररत, म ल य क स गणन Computation of Ceiling Price based on Aug-2015 Data under Para 4 of DPCO 2013 Number of Companies cosisting of Market Share of 1% & Above 3 21.5.1 Clomiphene Capsule 50 mg Per Capsule Sum of MAT value considered for price calculation (in Lakhs) 929.52 Sum of PTR per unit considered for price calculation 75.51 Number of Packs considered 3 Average PTR 25.17 Add : 16% Retailer Margin 4.03 Ceiling Price (without local taxes) (wef. 10.03.2016 ) 29.20 % Reduction with compared to Highest Price 33.66% WPI Reduction wef 1.4.2016 @ -2.7105% 0.79 WPI Increase wef 01.4.2017 @ 1.97186% 0.56 Final Ceiling Price ( wef. 01.4.2017 or date of notification, whichever is later) 28.97 Minimum Price (Rs.) 14.63 Maximum Price (Rs.) 37.94 Average of all considered (Rs.) 25.17 Ceiling Price (Rs.) 29.20 Unique as per TOTAL MAT 92,952,152 100% Strength Pack Size Unit PTR (Rs.) MAT (Rs.) SKU wise MAT % Qualify (Y/N) Y=Yes N=No Unit 1 21.5.1 CLOMIFENE G3G2 BESTOVA 50 MG CAPSULE 5 BESTOVA AKUMENTIS HEALTHCARE LTD 50 MG 5 CAPSULE 189.71 28,626,669.87 30.80% Y 37.94 37.94 2 CLOMIFENE G3G2 UBIPHENE N 50 MG CAPSULE 5 UBIPHENE N FOURRTS INDIA LABORATORIES PVT. LTD 50 MG 5 CAPSULE 114.72 12,344,560.32 13.28% Y 22.94 22.94 3 CLOMIFENE G3G2 OVAA SHIELD 50 MG CAPSULE 25 OVAA SHIELD SHIELD PHARMACEUTICALS 50 MG 25 CAPSULE 365.71 51,980,922.27 55.92% Y 14.63 14.63

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013 Number of Companies consisting of Market Share of 1% & Above 1 12.1.3 Diltiazem Capsule 60 mg Per Capsule Sum of MAT value considered for price calculation (in Lakhs) 0.02 PTR under Consideration 5.11 % Reduction with compared to Highest Price (average) 2.73% Reduction as per Monopoly condition 0.14 PTR after Reduction 4.97 Add : 16% Retailer Margin 0.80 Ceiling Price (without local taxes) (wef. 10.3.2016) 5.77 WPI Reduction wef 1.4.2016 @ -2.7105% 0.16 WPI Increase wef 01.4.2017 @ 1.97186% 0.11 Final Ceiling Price (without local taxes) (wef. 01.4.2017 or date of notification, whichever is later) 5.72 A. List of Item Under consideration TOTAL MAT 1,534 Unique as per Strength Pack Size Unit PTR (Rs.) MAT (Rs.) MAT (%) Unit Considered (Rs.) 1 12.1.3 DILTIAZEM C8A6 ANGIZEM DP 60 MG CAPSULE 10 ANGIZEM DP SUN PHARMA LABORATORIES LTD. 60 MG 10 CAPSULE 51.12 1533.6 100.00% 5.11 B. Computation of Average rate of Reduction under Monopoly Drug(s) Strength Description Route of Administration/ Dosage Form & packsize/packing, if any O. number & date Reduction with reference to the highest PTR under 2015 (%) 1 Diltiazem SR Tablet 90 mg DiltiazemSR Tablet 90 mg Tablet 1254(E) dated 29.3.2016 3.28 2 Diltiazem Tablet 30 mg DiltiazemTablet 30 mg Tablet 2195(E) dated 23.6.2016 2.48 3 Diltiazem Tablet 60 mg DiltiazemTablet 60 mg Tablet 2195(E) dated 23.6.2016 2.43 4 Diltiazem Injection 5 mg/ml DiltiazemInjection 5 mg/ml Injection 4128(E) dated 22.12.2016 2.73 Average Reduction 2.73

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013 Number of Companies consisting of Market Share of 1% & Above 1 2.1.2 Diclofenac Capsule 50 mg Per Capsule Sum of MAT value considered for price calculation (in Lakhs) 0.05 PTR under Consideration 0.60 % Reduction with compared to Highest Price (average) 15.02% Reduction as per Monopoly condition 0.09 PTR after Reduction 0.51 Add : 16% Retailer Margin 0.08 Ceiling Price (without local taxes) (wef. 10.3.2016) 0.59 WPI Reduction wef 1.4.2016 @ -2.7105% 0.02 WPI Increase wef 01.4.2017 @ 1.97186% 0.01 Final Ceiling Price (without local taxes) (wef. 01.4.2017 or date of notification, whichever is later) 0.58 A. List of Item Under consideration TOTAL MAT 4,720 Unique as per Strength Pack Size Unit PTR (Rs.) MAT (Rs.) MAT (%) Unit Considered (Rs.) 1 2.1.2 DICLOFENAC M1A12 TROMAX 50 MG CAPSULE 10 TROMAX ARISTO PHARMACEUTICALS PVT.LTD 50 MG 10 CAPSULE 5.96 4720 100.00% 0.60 B. Computation of Average rate of Reduction under Monopoly Drug(s) Strength Description Route of Administration/ Dosage Form & packsize/packing, if any O. number & date Reduction with reference to the highest PTR under 2015 (%) 1 Diclofenac 50mg Tablet Diclofenac50mg Tablet Tablet 1951(E) dated 2.6.2016 15.14 2 Diclofenac Injection 25 mg/ml DiclofenacInjection 25 mg/ml Injection 4128(E) dated 22.12.2016 14.89 Average Reduction 15.02

ड प स ओ 2013 क प र 4 क तहत, अगस त 2015 क आ कड क आध ररत, म ल य क स गणन Computation of Ceiling Price based on Aug-2015 Data under Para 4 of DPCO 2013 Number of Companies cosisting of Market Share of 1% & Above 1 2.1.3 Ibuprofen Capsule 400 mg Per Capsule Sum of MAT value considered for price calculation (in Lakhs) 2.58 Sum of PTR per unit considered for price calculation 0.87 Number of Packs considered 1 Average PTR 0.87 Add : 16% Retailer Margin 0.14 Ceiling Price (without local taxes) (wef. 10.03.2016 ) 1.01 % Reduction with compared to Highest Price 0.00% WPI Reduction wef 1.4.2016 @ -2.7105% 0.03 WPI Increase wef 01.4.2017 @ 1.97186% 0.02 Final Ceiling Price ( wef. 01.4.2017 or date of notification, whichever is later) 1.00 O. 3029(E) dated 23.12.2010 Minimum Price (Rs.) 0.87 Ceiling Price as per DPCO, 1995 Maximum Price (Rs.) 0.87 7.14/10's+6.18% ED+10% p.a. For 3 years 1.01 Per Capsule Average of all considered (Rs.) 0.87 Derived Ceiling PTR 0.87 Ceiling Price (Rs.) 1.01 Unique as per TOTAL MAT 259,365 100% Strength Pack Size Unit PTR (Rs.) MAT (Rs.) SKU wise Qualify MAT % (Y/N) Y=Yes N=No Unit 1 2.1.3 IBUPROFEN M1A30 FENLONG 400 MG CAPSULE 10 FENLONG SH PHARMACEUTICALS LTD 400 MG 10 CAPSULE 21.07 257,611 99.32% Y 2.11 0.87 2 IBUPROFEN M1A30 BRUFEN SOFTRA 400 MG CAPSULE 10 BRUFEN ABBOTT INDIA LTD. 400 MG 10 CAPSULE 12.90 1,754 0.68% N 1.29

ड प स ओ 2013 क प र 4 क तहत, अगस त 2015 क आ कड क आध ररत, म ल य क स गणन Computation of Ceiling Price based on Aug-2015 Data under Para 4 of DPCO 2013 Number of Companies cosisting of Market Share of 1% & Above 1 6.2.3.3 Rifampicin Tablet 150 mg Per Tablet Sum of MAT value considered for price calculation (in Lakhs) 0.53 Sum of PTR per unit considered for price calculation 1.55 Number of Packs considered 1 Average PTR 1.55 Add : 16% Retailer Margin 0.25 Ceiling Price (without local taxes) (wef. 10.03.2016 ) 1.80 % Reduction with compared to Highest Price 0.00% WPI Reduction wef 1.4.2016 @ -2.7105% 0.05 WPI Increase wef 01.4.2017 @ 1.97186% 0.03 Final Ceiling Price ( wef. 01.4.2017 or date of notification, whichever is later) 1.78 O. 836(E) dated 15.6.2005 Minimum Price (Rs.) 1.55 Ceiling Price as per DPCO, 1995 Maximum Price (Rs.) 1.55 13.33/10's+6.18% ED+10% p.a. For 3 years 1.88 Per Tablet Average of all considered (Rs.) 1.55 Derived Ceiling PTR 1.62 Ceiling Price (Rs.) 1.80 Unique as per TOTAL MAT 53,477 100% Strength Pack Size Unit PTR (Rs.) MAT (Rs.) SKU wise Qualify MAT % (Y/N) Y=Yes N=No Unit 1 6.2.3.3 RIFAMPICIN J4A12 R-CIN 150 MG TABLET 20 R-CIN LUPIN LTD 150 MG 20 TABLET 30.98 53477 100.00% Y 1.55 1.55